High-Dose Lipid Binding Protein Complexes for Rapid Leukocytosis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leukocytosis, endothelial dysfunction, and carditis are inadequate in providing rapid and effective relief, particularly in acute conditions such as acute coronary syndrome and stroke.
Innovation Solution
Administering a high dose of a lipid binding protein-based complex, such as CER-001, which mimics nascent discoidal pre-beta HDL, over a short period with multiple administrations to reduce inflammatory cytokines, white blood cell count, and serum levels of ICAM-1 and VCAM-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If current treatments are used for leukocytosis, endothelial dysfunction, and carditis, then treatment is provided, but the relief is not rapid or effective enough in acute conditions
Solution Approach 1:
The patent changes the dosage parameter from standard chronic disease doses to high doses specifically for acute conditions. CER-001 is administered at high doses (e.g., 10-50 mg/kg or higher) over short periods (2 days to 2 weeks) to achieve rapid reduction of inflammatory markers and white blood cell counts, directly addressing the need for faster and more effective treatment in acute settings
2Productivity
If high dose lipid binding protein-based complex is administered over a short period, then rapid improvement in biomarkers is achieved, but multiple administrations are required
Solution Approach 1:
The patent implements periodic administration of CER-001 at high doses over short intervals (multiple doses over 2 days to 2 weeks) to achieve rapid therapeutic effect. This periodic high-dose strategy produces quick improvement in inflammatory biomarkers while allowing for controlled repetition of treatments to maintain efficacy
3Reliability
If high dose therapy is used for acute conditions, then rapid clinical benefit is achieved, but the dose is higher than what would be used for chronic conditions
Solution Approach 1:
The patent applies local quality by tailoring the dosage regimen specifically to the acute condition context rather than using a universal dose. High doses of CER-001 are prescribed specifically for acute conditions (leukocytosis, endothelial dysfunction, carditis) while recognizing that chronic conditions require different, lower dosing strategies, thus optimizing treatment for the specific pathological state
Data Source
AI summary
Methods for treating leukocytosis, endothelial dysfunction, and carditis comprising administering to a subject a lipid binding protein-based complex.